Prognostic Impact of 9-Month High-Sensitivity C-Reactive Protein Levels on Long-Term Clinical Outcomes and In-Stent Restenosis in Patients at 9 Months After Drug-Eluting Stent Implantation

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Sep 26

PMID 26406989

Citations 3

Authors

I-Chang Hsieh

Chun-Chi Chen

Ming-Jer Hsieh

Chia-Hung Yang

Dong-Yi Chen

Shang-Hung Chang

Chao-Yung Wang

Cheng-Hung Lee

Ming-Lung Tsai

Affiliations

Soon will be listed here.

Abstract

Introduction: The level of 9-month high-sensitivity C-reactive protein (hsCRP) in predicting cardiovascular outcomes is scanty in patients at 9 months after receiving drug-eluting stent (DES) implantations. This study aims to evaluate the relationship between 9-month follow-up hsCRP levels and long-term clinical outcomes in patients at 9 months after receiving DES.

Methods: A total of 1,763 patients who received 9-month follow-up angiography were enrolled and grouped according to hsCRP level 9 months after the DES implantation: group I (718 patients, hsCRP<1.0 mg/L), group II (639 patients, 1.0 ≦ hsCRP ≦ 3.0 mg/L), and group III (406 patients, hsCRP>3.0 mg/L).

Results: Group III patients had a lower cardiovascular event-free survival rate than group I or II patients during a follow-up of 64 ± 45 months (64.5% vs. 71.6% vs. 72.8%, respectively, p = 0.012). Multivariate analysis showed that a follow-up hsCRP level <3.0 mg/L was an independent predictor of a major adverse cardiovascular event (cardiac death, reinfarction, target lesion revascularization, stenting in a new lesion, or coronary bypass surgery). Group III patients had a higher restenosis rate (11.3% vs. 5.8% vs. 6.6%, respectively, p = 0.002) and loss index (0.21 ± 0.32 vs. 0.16 ± 0.24 vs. 0.18 ± 0.28, respectively, p = 0.001) than group I or II patients in 9-month follow-up angiography.

Conclusions: A high 9-month follow-up hsCRP level is an independent predictor of long-term clinical cardiovascular outcomes in patients at 9 months after DES implantation. It is also associated with a higher restenosis rate, larger late loss and loss index at 9 months after DES implantation.

Citing Articles

Comprehensive analysis of predictive factors for rapid angiographic stenotic progression and restenosis risk in coronary artery disease patients underwent percutaneous coronary intervention with drug-eluting stents implantation.

Wu Y, Fu X J Clin Lab Anal. 2018; 33(2):e22666.

PMID: 30221497 PMC: 6818547. DOI: 10.1002/jcla.22666.

Impact of hyperuricemia on clinical outcomes after percutaneous coronary intervention for in-stent restenosis.

Joo H, Jeong H, Kook H, Lee S, Park J, Hong S BMC Cardiovasc Disord. 2018; 18(1):114.

PMID: 29890945 PMC: 5996510. DOI: 10.1186/s12872-018-0840-2.

Preprocedural C-Reactive Protein Predicts Outcomes after Primary Percutaneous Coronary Intervention in Patients with ST-elevation Myocardial Infarction a systematic meta-analysis.

Mincu R, Janosi R, Vinereanu D, Rassaf T, Totzeck M Sci Rep. 2017; 7:41530.

PMID: 28128312 PMC: 5270244. DOI: 10.1038/srep41530.

References

Segev A, Kassam S, Buller C, Lau H, Sparkes J, Connelly P . Pre-procedural plasma levels of C-reactive protein and interleukin-6 do not predict late coronary angiographic restenosis after elective stenting. Eur Heart J. 2004; 25(12):1029-35. DOI: 10.1016/j.ehj.2004.04.027. View

Dibra A, Mehilli J, Braun S, Hadamitzky M, Baum H, Dirschinger J . Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting. Am J Med. 2003; 114(9):715-22. DOI: 10.1016/s0002-9343(03)00183-9. View

Le J, Vilcek J . Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest. 1989; 61(6):588-602. View

Pietila K, Harmoinen A, Teppo A . Acute phase reaction, infarct size and in-hospital morbidity in myocardial infarction patients treated with streptokinase or recombinant tissue type plasminogen activator. Ann Med. 1991; 23(5):529-35. DOI: 10.3109/07853899109150513. View

Haverkate F, Thompson S, Pyke S, Gallimore J, Pepys M . Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997; 349(9050):462-6. DOI: 10.1016/s0140-6736(96)07591-5. View

Ross R . Atherosclerosis--an inflammatory disease. N Engl J Med. 1999; 340(2):115-26. DOI: 10.1056/NEJM199901143400207. View

Khera A, McGuire D, Murphy S, Stanek H, Das S, Vongpatanasin W . Race and gender differences in C-reactive protein levels. J Am Coll Cardiol. 2005; 46(3):464-9. DOI: 10.1016/j.jacc.2005.04.051. View

Yip H, Hung W, Yang C, Chen Y, Cheng C, Chen S . Serum concentrations of high-sensitivity C-reactive protein predict progressively obstructive lesions rather than late restenosis in patients with unstable angina undergoing coronary artery stenting. Circ J. 2005; 69(10):1202-7. DOI: 10.1253/circj.69.1202. View

Palmerini T, Marzocchi A, Marrozzini C, Ortolani P, Saia F, Bacchi-Reggiani L . Preprocedural levels of C-reactive protein and leukocyte counts predict 9-month mortality after coronary angioplasty for the treatment of unprotected left main coronary artery stenosis. Circulation. 2005; 112(15):2332-8. DOI: 10.1161/CIRCULATIONAHA.105.551648. View

10.

Gaspardone A, Versaci F, Tomai F, Citone C, Proietti I, Gioffre G . C-Reactive protein, clinical outcome, and restenosis rates after implantation of different drug-eluting stents. Am J Cardiol. 2006; 97(9):1311-6. DOI: 10.1016/j.amjcard.2005.11.060. View

11.

Hong S, Kim M, Ahn T, Ahn Y, Bae J, Shim W . Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes. Heart. 2006; 92(8):1119-24. PMC: 1861125. DOI: 10.1136/hrt.2005.075960. View

12.

Park D, Lee C, Yun S, Kim Y, Hong M, Kim J . Prognostic impact of preprocedural C reactive protein levels on 6-month angiographic and 1-year clinical outcomes after drug-eluting stent implantation. Heart. 2007; 93(9):1087-92. PMC: 1955033. DOI: 10.1136/hrt.2006.099762. View

13.

Delhaye C, Sudre A, Lemesle G, Marechaux S, Broucqsault D, Hennache B . Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention. Cardiovasc Revasc Med. 2009; 10(3):144-50. DOI: 10.1016/j.carrev.2009.01.005. View

14.

Li J, Ren Y, Chen K, Yeung A, Xu B, Ruan X . Impact of C-reactive protein on in-stent restenosis: a meta-analysis. Tex Heart Inst J. 2010; 37(1):49-57. PMC: 2829784. View

15.

Xu Y, Li J, Xu B, Zhu C, Yang Y, Chen J . Role of plasma C-reactive protein in predicting in-stent restenosis in patients with stable angina after coronary stenting. Chin Med J (Engl). 2011; 124(6):845-50. View

16.

Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L . Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med. 2000; 343(16):1139-47. DOI: 10.1056/NEJM200010193431602. View

17.

Gottsauner-Wolf M, Zasmeta G, Hornykewycz S, Nikfardjam M, Stepan E, Wexberg P . Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J. 2000; 21(14):1152-8. DOI: 10.1053/euhj.1999.1987. View

18.

Herrmann J, Lennon R, Barsness G, Sandhu G, Gulati R, Best P . High sensitivity C-reactive protein and outcomes following percutaneous coronary intervention in contemporary practice. Circ Cardiovasc Interv. 2012; 5(6):783-90. DOI: 10.1161/CIRCINTERVENTIONS.112.972182. View

19.

Versaci F, Gaspardone A, Tomai F, Crea F, Chiariello L, Gioffre P . Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation. Am J Cardiol. 2000; 85(1):92-5, A8. DOI: 10.1016/s0002-9149(99)00612-8. View

20.

Walter D, Fichtlscherer S, Sellwig M, Auch-Schwelk W, Schachinger V, Zeiher A . Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol. 2001; 37(3):839-46. DOI: 10.1016/s0735-1097(00)01193-1. View